273 related articles for article (PubMed ID: 14556456)
1. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Drouet L
Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
[TBL] [Abstract][Full Text] [Related]
2. [New and future antithrombotic agents in thrombo-embolic venous disease].
Drouet L
Rev Prat; 2003 Jan; 53(1):58-61. PubMed ID: 12673926
[TBL] [Abstract][Full Text] [Related]
3. [The new antithrombotic agents].
Meyer Samama M
Presse Med; 2005 Oct; 34(18):1309-14. PubMed ID: 16269995
[TBL] [Abstract][Full Text] [Related]
4. [Deep vein thrombosis: new drugs and future therapeutic perspectives].
García Vidal R; Berga Fauria C; Paredero VM
Rev Clin Esp; 2006 Jun; 206(6):281-3. PubMed ID: 16762292
[TBL] [Abstract][Full Text] [Related]
5. [New anticoagulants -- their clinical significance].
Haas S
Ther Umsch; 2003 Jan; 60(1):19-23. PubMed ID: 12638473
[TBL] [Abstract][Full Text] [Related]
6. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Leone G; Rossi E; Leone AM; De Stefano V
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
[TBL] [Abstract][Full Text] [Related]
7. [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
Falciani M; Imberti D; Prisco D
Recenti Prog Med; 2005 Apr; 96(4):196-204. PubMed ID: 15932039
[TBL] [Abstract][Full Text] [Related]
8. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Harenberg J; Wehling M
Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
[TBL] [Abstract][Full Text] [Related]
9. New anticoagulants for the prevention and treatment of venous thromboembolism.
McRae SJ; Ginsberg JS
Vasc Health Risk Manag; 2005; 1(1):41-53. PubMed ID: 17319097
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
11. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
12. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of deep vein thrombosis with ximelagatran].
Caspary L; Bauersachs R; Brehme S; Creutzig A; Harenberg J; Hoffmann U; Landgraf H; Schellong S
Dtsch Med Wochenschr; 2004 Jul; 129(30):1635-40. PubMed ID: 15257504
[No Abstract] [Full Text] [Related]
14. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Andersen JC
Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran--a promising new drug in thromboembolic disorders.
Petersen P
Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-acting synthetic pentasaccharides.
Koopman MM; Büller HR
J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
[TBL] [Abstract][Full Text] [Related]
17. [Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors].
Puccio D; Montalto S; Valerio MC; Ventimiglia A; Caronia A; Novo S
G Ital Cardiol (Rome); 2006 Nov; 7(11):739-46. PubMed ID: 17216915
[TBL] [Abstract][Full Text] [Related]
18. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
Agnelli G
Drugs; 2004; 64 Suppl 1():47-52. PubMed ID: 15586627
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.
Drouet L; Bal Dit Sollier C
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():21-6. PubMed ID: 15701144
[TBL] [Abstract][Full Text] [Related]
20. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
